N/A
N=10
SleepFlexTM Treatment of Obstructive Sleep Apnea
Obstructive Sleep Apnea
Bottom Line
View on ClinicalTrials.gov: NCT04726514 ↗Enrolled (actual)
10
Serious AEs
0.0%
Results posted
Jun 2023
Primary outcome: Primary: Number of Participants With Freedom From SleepFlex-related Serious Adverse Events — 10 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- SleepFlex (Device)
- Age
- Adult, Older Adult · 21+ yrs
- Sex
- All
- Sponsor
- Berendo Scientific, LLC
- Primary completion
- Apr 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Freedom From SleepFlex-related Serious Adverse Events |
10 | — |
| PRIMARY Change in the Apnea-hypopnea Index (AHI) |
2.9 | — |
| SECONDARY Number of Participants With Development of Side Effects: Mouth, Throat, or Neck Pain; Dysphagia |
— | — |
Summary
The purpose of this study is to evaluate the safety and effectiveness of the SleepFlex program for treatment of mild to moderate OSA
Eligibility Criteria
Inclusion Criteria
- Age 21 years and older
- Mild to moderate OSA, defined as AHI >10 - 30 events/hour, documented by polysomnogram or home sleep apnea test within 180 days prior to study enrollment
- Central or mixed disordered breathing events (≤25% of total number of events)
- Unable to tolerate or decline positive airway pressure therapy
- Body mass index ≤32 kg/m2
- Able to protrude tongue ≥20 mm beyond maxillary incisors
- Absence of markedly enlarged tonsils, defined as 3+ or 4+ according to the Brodsky classification
- No uncontrolled sleep disorder other than OSA such as narcolepsy, chronic insomnia, restless legs syndrome, or REM behavior disorder
- Absence of excessive daytime sleepiness, defined by Epworth Sleepiness Scale score >10
- No uncontrolled nasal obstruction
- Absence of moderate to severe mandibular insufficiency
- No previous surgery involving the oral cavity or pharynx other than tonsillectomy
- No previous radiation therapy to the head and neck
- No known neurologic, cardiac (other than hypertension controlled with a single medication), pulmonary, renal, hepatic, or psychiatric disorders
- No psychiatric diagnoses other than treated depression or mild anxiety
- Stable medication regimen for ≥1 month
- No acute illness or infection
- Ownership of personal smartphone with iOS or Android operating system
- No known hypersensitivity to any material of the SleepFlex devices
Exclusion Criteria
- Unwilling or unable to provide informed written consent in English
- Pregnancy, breastfeeding, or plans to become pregnant
- Smoker (tobacco or recreational drugs) in the past month
- Alcohol consumption, averaged over the previous month, greater than 2 alcoholic beverages per day
- Significant vision or hearing problems
- Unwilling or incapable of returning for all follow-up visits and conduct sleep studies at home, including the evaluation procedures and filling out questionnaires
- Any other reason the investigator determines as being unfit for study participation
Data sourced from ClinicalTrials.gov (NCT04726514). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.